vs
Esperion Therapeutics, Inc.（ESPR）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Esperion Therapeutics, Inc.的1.3倍（$217.4M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 0.5%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.0%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
ESPR vs RPD — 直观对比
营收规模更大
RPD
是对方的1.3倍
$168.4M
营收增速更快
ESPR
高出143.2%
0.5%
两年增速更快
ESPR
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $217.4M |
| 净利润 | — | $3.1M |
| 毛利率 | — | 68.9% |
| 营业利润率 | 50.6% | 1.0% |
| 净利率 | — | 1.4% |
| 营收同比 | 143.7% | 0.5% |
| 净利润同比 | — | 44.1% |
| 每股收益（稀释后） | $0.32 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRRPD
| Q4 25 | $168.4M | $217.4M | ||
| Q3 25 | $87.3M | $218.0M | ||
| Q2 25 | $82.4M | $214.2M | ||
| Q1 25 | $65.0M | $210.3M | ||
| Q4 24 | $69.1M | $216.3M | ||
| Q3 24 | $51.6M | $214.7M | ||
| Q2 24 | $73.8M | $208.0M | ||
| Q1 24 | $137.7M | $205.1M |
净利润ESPRRPD
| Q4 25 | — | $3.1M | ||
| Q3 25 | $-31.3M | $9.8M | ||
| Q2 25 | $-12.7M | $8.3M | ||
| Q1 25 | $-40.5M | $2.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $-29.5M | $15.4M | ||
| Q2 24 | $-61.9M | $6.5M | ||
| Q1 24 | $61.0M | $1.4M |
毛利率ESPRRPD
| Q4 25 | — | 68.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.6% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 70.7% | ||
| Q1 24 | — | 70.3% |
营业利润率ESPRRPD
| Q4 25 | 50.6% | 1.0% | ||
| Q3 25 | -11.4% | 2.7% | ||
| Q2 25 | 8.6% | 1.6% | ||
| Q1 25 | -34.0% | -0.0% | ||
| Q4 24 | -6.4% | 3.4% | ||
| Q3 24 | -31.0% | 6.0% | ||
| Q2 24 | 3.5% | 2.5% | ||
| Q1 24 | 52.5% | 4.7% |
净利率ESPRRPD
| Q4 25 | — | 1.4% | ||
| Q3 25 | -35.9% | 4.5% | ||
| Q2 25 | -15.4% | 3.9% | ||
| Q1 25 | -62.2% | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | -57.2% | 7.2% | ||
| Q2 24 | -83.9% | 3.1% | ||
| Q1 24 | 44.3% | 0.7% |
每股收益（稀释后）ESPRRPD
| Q4 25 | $0.32 | $0.05 | ||
| Q3 25 | $-0.16 | $0.15 | ||
| Q2 25 | $-0.06 | $0.13 | ||
| Q1 25 | $-0.21 | $0.03 | ||
| Q4 24 | $-0.14 | $0.08 | ||
| Q3 24 | $-0.15 | $0.21 | ||
| Q2 24 | $-0.33 | $0.09 | ||
| Q1 24 | $0.34 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $154.7M |
| 总资产 | $465.9M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRRPD
| Q4 25 | $167.9M | $474.7M | ||
| Q3 25 | $92.4M | $407.1M | ||
| Q2 25 | $86.1M | $511.7M | ||
| Q1 25 | $114.6M | $493.5M | ||
| Q4 24 | $144.8M | $521.7M | ||
| Q3 24 | $144.7M | $443.7M | ||
| Q2 24 | $189.3M | $442.6M | ||
| Q1 24 | $226.6M | $411.7M |
股东权益ESPRRPD
| Q4 25 | $-302.0M | $154.7M | ||
| Q3 25 | $-451.4M | $127.2M | ||
| Q2 25 | $-433.5M | $90.4M | ||
| Q1 25 | $-426.2M | $52.7M | ||
| Q4 24 | $-388.7M | $17.7M | ||
| Q3 24 | $-370.2M | $-5.1M | ||
| Q2 24 | $-344.2M | $-52.6M | ||
| Q1 24 | $-294.3M | $-86.4M |
总资产ESPRRPD
| Q4 25 | $465.9M | $1.7B | ||
| Q3 25 | $364.0M | $1.7B | ||
| Q2 25 | $347.1M | $1.6B | ||
| Q1 25 | $324.0M | $1.6B | ||
| Q4 24 | $343.8M | $1.7B | ||
| Q3 24 | $314.1M | $1.6B | ||
| Q2 24 | $352.3M | $1.5B | ||
| Q1 24 | $373.1M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.4M |
| 自由现金流率自由现金流/营收 | — | 16.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | — | $146.2M |
8季度趋势，按日历期对齐
经营现金流ESPRRPD
| Q4 25 | $45.2M | $37.6M | ||
| Q3 25 | $-4.3M | $39.0M | ||
| Q2 25 | $-31.4M | $47.5M | ||
| Q1 25 | $-22.6M | $29.8M | ||
| Q4 24 | $-35.0M | $63.8M | ||
| Q3 24 | $-35.3M | $44.0M | ||
| Q2 24 | $-7.2M | $32.9M | ||
| Q1 24 | $53.8M | $31.1M |
自由现金流ESPRRPD
| Q4 25 | — | $36.4M | ||
| Q3 25 | — | $34.8M | ||
| Q2 25 | — | $46.6M | ||
| Q1 25 | — | $28.4M | ||
| Q4 24 | — | $62.6M | ||
| Q3 24 | $-35.5M | $42.6M | ||
| Q2 24 | $-7.3M | $32.6M | ||
| Q1 24 | $53.8M | $30.4M |
自由现金流率ESPRRPD
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 16.0% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 13.5% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | -68.7% | 19.9% | ||
| Q2 24 | -9.9% | 15.7% | ||
| Q1 24 | 39.0% | 14.8% |
资本支出强度ESPRRPD
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.3% | 0.6% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.3% |
现金转化率ESPRRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | — | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | 0.88× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
